Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile.
Although effective in treating a range of childhood psychiatric conditions, selective serotonin reuptake inhibitors (SSRI) have been implicated in the induction of an "activation syndrome" (characterized by symptoms of irritability, restlessness, emotional labiality, etc.) that may represent an intermediary state change that fosters suicidality. SSRI-induced activation syndrome is well-accepted by many clinicians and thought to be relatively common, particularly in children and teens. However, gaps exist in empirical data on phenomenology and tools for early detection. With this in mind, we report on a recently funded National Institutes of Health grant to develop a measure of behavioral activation to be completed in a clinical setting. We discuss the development of this measure-the Treatment-Emergent Activation and Suicidality Assessment Profile (TE-ASAP)-as well as psychometric results from a sample of youth with internalizing disorders who were at varying stages of SSRI treatment. Overall, psychometric data were quite promising, with the TE-ASAP demonstrating excellent reliability (i.e., internal consistency, inter-rater, short-term test-retest stability) and strong validity properties. Through further evaluation of the TE-ASAP in the context of a controlled multimodal trial in youth with obsessive-compulsive disorder, we hope to augment understanding of activation syndrome and, in turn, mitigate risks through early detection of this potentially lifethreatening adverse effect.
Reid
Jeannette M
JM
Department of Pediatrics, University of South Florida, 800 6th Street South 4th Floor, St. Petersburg, FL 33701, USA.
Storch
Eric A
EA
Murphy
Tanya K
TK
Bodzin
Danielle
D
Mutch
P Jane
PJ
Lehmkuhl
Heather
H
Aman
Michael
M
Goodman
Wayne K
WK
JAMA. 1998 Nov 25;280(20):1752-6
9842950
J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):222-9
11211371
Child Adolesc Psychiatry Ment Health. 2009 Jan 30;3(1):4
19183470
Am J Psychiatry. 2007 Sep;164(9):1356-63
17728420
BMJ. 2003 May 10;326(7397):1014
12742924
Br J Psychiatry. 1989 May;154:672-6
2574607
J Clin Psychiatry. 1996 Sep;57(9):415-21
9746450
JAMA. 2004 Oct 27;292(16):1969-76
15507582
Am J Psychiatry. 1990 Feb;147(2):207-10
2301661
J Am Acad Child Adolesc Psychiatry. 2002 Nov;41(11):1350-9
12410078
Drug Saf. 1993 Mar;8(3):186-212
8452661
Biol Psychiatry. 2006 Nov 1;60(9):951-6
16730333
Int Rev Psychiatry. 2008 Apr;20(2):203-8
18386213
JAMA. 2007 Apr 18;297(15):1683-96
17440145
CMAJ. 2009 Feb 3;180(3):291-7
19188627
Assessment. 2008 Sep;15(3):317-28
18310593
JAMA. 2004 Aug 18;292(7):807-20
15315995
Psychopharmacology (Berl). 2007 Mar;191(1):87-96
17180618
CNS Spectr. 2008 Sep;13(9 Suppl 14):37-46
18849910
BMJ. 1991 Sep 21;303(6804):685-92
1833012
N Engl J Med. 2008 Dec 25;359(26):2753-66
18974308
J Abnorm Child Psychol. 1996 Dec;24(6):735-47
8970907